TPC
LYEL icon

Takeda Pharmaceutical Company’s Lyell Immunopharma LYEL Stock Holding History

Takeda Pharmaceutical Company’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$891K Buy
54,887
+13,722
+33% +$157K 5.45% 5
2025
Q2 		$364K Sell
41,165
-1
-0% -$9 1.86% 7
2025
Q1 		$443K Hold
41,166
– – 2.74% 7
2024
Q4 		$527K Buy
+41,166
New +$816K 1.98% 7

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Takeda Pharmaceutical Company's LYEL Position: Q3 2025 in Review

Takeda Pharmaceutical Company increased its Lyell Immunopharma (LYEL) stake by 33% in Q3 2025, buying an estimated $157K and bringing the position to 54,887 shares worth $891K. The position accounts for 5.45% of the portfolio, ranked #5.

Takeda Pharmaceutical Company first reported a position in LYEL in Q4 2024 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold LYEL as of Q3 2025.

  • Takeda Pharmaceutical Company held 54,887 shares of Lyell Immunopharma worth $891K as of Q3 2025.
  • Takeda Pharmaceutical Company bought 13,722 Lyell Immunopharma shares in Q3 2025, an estimated $157K.
  • Lyell Immunopharma made up 5.45% of Takeda Pharmaceutical Company's portfolio in Q3 2025, its #5 holding.
  • Takeda Pharmaceutical Company first reported a position in Lyell Immunopharma in Q4 2024 and has held it in 4 quarters since.
  • 59 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.